Dr. Lal Path Labs Ltd. (LALPATHLAB) Q2 FY27 Financial Results: PAT ₹170 Cr & Revenue ₹798 Cr

Investor Takeaways

• Revenue grew 19.1% YoY to ₹798 crores in Q1 FY27
• PAT increased 27.2% YoY to ₹170 crores
• EBITDA rose 28.7% YoY to ₹247 crores
• Interim dividend declared at ₹5 per share
• Targeting mid-teens revenue growth and 27-28% EBITDA margins

Key Financial Highlights

What Changed

The company demonstrated strong operational momentum in Q1 FY27, with revenue growth outpacing profit growth, indicating improved operational efficiency. PAT growth (27.2%) exceeded revenue growth (19.1%), suggesting effective cost management. EBITDA growth (28.7%) was the highest among key metrics, reflecting robust operating performance. The 8.2% patient volume growth and 10.7% sample volume growth (+10.7% YoY) drove the top-line expansion, supported by rural outreach across 7 states (110,000 patients tested) and GenAI tools like SwasthAI. Rural revenue now constitutes 39% of total revenue, with suburban business in West India showing double-digit growth post-LIMS integration. Gross margins stabilized near 81% despite realization improvements, with reinvestment prioritizing network expansion over margin upgrades. Management deferred pricing adjustments to H2, targeting mid-teens revenue growth and 27-28% EBITDA margins. Strategic acquisitions in Ghana and India are planned, with international operations currently contributing less than 5% of revenue, targeting long-term growth over 3-5 years. The 50% interim dividend (₹5/share) reflects confidence in sustained cash flow generation.

Peer Comparison

Dr. Lal PathLabs trades at a premium to Sun Pharmaceutical (P/E 63.61 vs 41.28) but below Divi's Laboratories (72.41), with no ROE/ROCE data provided for comparison. The company's valuation reflects growth expectations relative to peers.

Risks & Concerns

No specific risks identified in this filing.

Quarterly Trend

The current Q1 FY27 revenue (₹798 Cr) and PAT (₹170 Cr) significantly exceed all previous quarters, indicating a notable acceleration in performance. OPM (25.81%) in Q3FY25 was lower than the current quarter's implied margin (not explicitly stated but inferred from PAT growth), though still within historical ranges. The PAT growth trajectory shows consistent improvement from ₹85.8 Cr (Q4FY24) to ₹170 Cr (Q1 FY27).